Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications. The KURA stock yearly return is shown above.
The yearly return on the KURA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KURA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|